Risk Factors for the Mortality of Patients With Coronavirus Disease 2019 Requiring Extracorporeal Membrane Oxygenation in a Non-Centralized Setting: A Nationwide Studyopen access
- Authors
- Kim, Tae Wan; Kim, Won-Young; Park, Sunghoon; Lee, Su Hwan; Park, Onyu; Kim, Taehwa; Yeo, Hye Ju; Jang, Jin Ho; Cho, Woo Hyun; Huh, Jin-Won; Lee, Sang-Min; Chung, Chi Ryang; Lee, Jongmin; Kim, Jung Soo; Lim, Sung Yoon; Baek, Ae-Rin; Yoo, Jung-Wan; Kim, Ho Cheol; Choi, Eun Young; Park, Chul; Kim, Tae-Ok; Moon, Do Sik; Lee, Song-, I; Moon, Jae Young; Kwon, Sun Jung; Seong, Gil Myeong; Jung, Won Jai; Baek, Moon Seong
- Issue Date
- Mar-2024
- Publisher
- 대한의학회
- Keywords
- COVID-19; Extracorporeal Membrane Oxygenation; Mortality; Age; Continuous Renal Replacement Therapy
- Citation
- Journal of Korean Medical Science, v.39, no.8
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- Journal of Korean Medical Science
- Volume
- 39
- Number
- 8
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2021.sw.kumedicine/65900
- DOI
- 10.3346/jkms.2024.39.e75
- ISSN
- 1011-8934
1598-6357
- Abstract
- Background: Limited data are available on the mortality rates of patients receiving extracorporeal membrane oxygenation (ECMO) support for coronavirus disease 2019 (COVID-19). We aimed to analyze the relationship between COVID-19 and clinical outcomes for patients receiving ECMO. Methods: We retrospectively investigated patients with COVID-19 pneumonia requiring ECMO in 19 hospitals across Korea from January 1, 2020 to August 31, 2021. The primary outcome was the 90 -day mortality after ECMO initiation. We performed multivariate analysis using a logistic regression model to estimate the odds ratio (OR) of 90 -day mortality. Survival differences were analyzed using the Kaplan-Meier (KM) method. Results: Of 127 patients with COVID-19 pneumonia who received ECMO, 70 patients (55.1%) died within 90 days of ECMO initiation. The median age was 64 years, and 63% of patients were male. The incidence of ECMO was increased with age but was decreased after 70 years of age. However, the survival rate was decreased linearly with age. In multivariate analysis, age (OR, 1.048; 95% confidence interval [CI], 1.010-1.089; P = 0.014) and receipt of continuous renal replacement therapy (CRRT) (OR, 3.069; 95% CI, 1.312-7.180; P = 0.010) were significantly associated with an increased risk of 90 -day mortality. KM curves showed significant differences in survival between groups according to age (65 years) (log -rank P = 0.021) and receipt of CRRT (log -rank P = 0.004). Conclusion: Older age and receipt of CRRT were associated with higher mortality rates with COVID-19 who received ECMO.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 5. Others > ETC > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.